(Q36301610)

13 August 2017

1 reference

title

Budesonide and formoterol combination for the treatment of chronic obstructive pulmonary disease (English)

1 reference

chronic obstructive pulmonary disease

13 August 2017

main subject

1 reference

Stefano Centanni

1

1 reference

13 August 2017

Fabiano Di Marco

series ordinal

2

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 November 2005

1 reference

Expert Opinion on Pharmacotherapy

13 August 2017

published in

1 reference

13 August 2017

volume

6

1 reference

13 August 2017

issue

14

1 reference

13 August 2017

page(s)

2525-2534

1 reference

Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2525

Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2525

Bronchodilator reversibility testing in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2525

Budesonide inhalation suspension: a review of its use in infants, children and adults with inflammatory respiratory disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2525

Budesonide/formoterol: in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2525

Alternative mechanisms for long-acting beta(2)-adrenergic agonists in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2525

Why are long-acting beta-adrenoceptor agonists long-acting?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2525

Inhaled combination therapy with long-acting beta 2-agonists and corticosteroids in stable COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2525

Protective effects of a glucocorticoid on downregulation of pulmonary beta 2-adrenergic receptors in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2525

Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2525

Interactions between corticosteroids and beta agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2525

Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2525

Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2525

Impact of preventing exacerbations on deterioration of health status in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2525

Use of oral corticosteroids and risk of fractures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2525

Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2525

The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2525

Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2525

The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2525

The costs of exacerbations in chronic obstructive pulmonary disease (COPD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2525

Patterns of hospitalization in elderly patients with asthma and chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2525

Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2525

Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2525

Fluticasone propionate/salmeterol for the treatment of chronic-obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2525

Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2525

Current and future pharmacologic therapy of exacerbations in chronic obstructive pulmonary disease and asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2525

The role of long-acting bronchodilators in the management of stable COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.14.2525

10.1517/14656566.6.14.2525

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference